Strategic partnership

CStone Pharmaceuticals announced Wednesday that it has entered into a strategic partnership and exclusive licensing agreement with Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc., for anti-PD-1 antibody Nofazinlimab in mainland China.

FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China

The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
2616.HK

Recent Articles

RELATED ARTICLES

  1. 111 Inc reports first ever opertaing profit
    Inaugural operating profit fails to lift 111 Inc.
    YI.US
  2. Margins ring alarm bells as 160 Health readies IPO 
  3. IFlytek hives off health unit to fund AI medical drive
    002230.SHE
  4. HealthyWay seeks Hong Kong IPO to staunch flow of red ink
  5. Tong Ren Tang Healthcare IPO banks on famous name, growth through M&A
  6. Third time’s the charm: Fangzhou finally finds winning tonic for Hong Kong IPO
    6086.HK
  7. Clinical trials come up short again for Alphamab Oncology
    9966.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva